Evidence map›Paper›PMID 35288446›Full record

ArticleBJGP open2022

Point-of-care NT-proBNP monitoring for heart failure: observational feasibility study in primary care.

Jason Chami, Susannah Fleming, Clare J Taylor, Clare R Bankhead, Tim James, Brian Shine, Julie McLellan, Fd Richard Hobbs, Rafael Perera

Abstract read
In one paragraph

Article in BJGP open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Sendaway capillary NT-proBNP in pulmonary hypertension.BMJ open respiratory research · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jason ChamiSydney Medical School, University of Sydney, Sydney, Australia.
Susannah FlemingNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK susannah.fleming@phc.ox.ac.uk.
Clare J TaylorNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Clare R BankheadNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-1588-3849
Tim JamesDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Brian ShineDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Julie McLellanNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Fd Richard HobbsNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Rafael PereraNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAround one million individuals in the UK have heart failure (HF), a chronic disease that causes significant morbidity and mortality. N-terminal pro-B-type natriuretic peptide (NT-proBNP) monitoring could help improve the care of patients with HF in the community.

aimThe aim of this study is to provide evidence to support the routine use of point-of-care (POC) NT-proBNP monitoring in primary care. DESIGN &

settingIn this observational cohort study, the Roche Cobas h 232 POC device was used to measure NT-proBNP in 27 patients with HF at 0, 6, and 12 months, with a subset reanalysed in the laboratory for comparison.

methodData were analysed for within-person and between-person variability and concordance with laboratory readings using Passing-Bablok regression. GPs reported whether POC results impacted clinical decisionmaking, and patients indicated their willingness to participate in long-term cohort studies using the Likert acceptability scale.

resultsWithin-person variability in POC NT-proBNP over 12 months was 881 pg/mL (95% confidence interval [CI] = 380 to 1382 pg/mL). Between-person variability was 1972 pg/mL (95% CI = 1,525 to 2791 pg/mL). Passing-Bablok regression showed no significant systematic difference between POC and laboratory measurements. Patients indicated a high level of acceptability, and GP decisionmaking was affected for at least one visit in a third of patients.

conclusionWithin-person variability in POC NT-proBNP is around half of between-person variability, so detecting changes could be of use in HF management. High patient acceptability and impact on clinical decisionmaking warrant further investigation in a larger long-term cohort study.

Indexed as

brain natriuretic peptidefamily practicegeneral practiceheart failurepoint-of-care testingprimary health care

Identifiers

PMID35288446
PMCPMC9680739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.